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Summary
AIMS OF THE STUDY: During the ongoing COVID-19
pandemic, the launch of a large-scale vaccination cam-
paign and virus mutations have hinted at possible changes
in transmissibility and the virulence affecting disease pro-
gression up to critical illness, and carry potential for future
vaccination failure. To monitor disease development over
time with respect to critically ill COVID-19 patients, we
report near real-time prospective observational data from
the RISC-19-ICU registry that indicate changed character-
istics of critically ill patients admitted to Swiss intensive
care units (ICUs) at the onset of a third pandemic wave.
METHODS: 1829 of 3344 critically ill COVID-19 patients
enrolled in the international RISC-19-ICU registry as of 31
May 2021 were treated in Switzerland and were included
in the present study. Of these, 1690 patients were admit-
ted to the ICU before 1 February 2021 and were compared
with 139 patients admitted during the emerging third pan-
demic wave
RESULTS: Third wave patients were a mean of 5.2 years
(95% confidence interval [CI] 3.2–7.1) younger (median
66.0 years, interquartile range [IQR] 57.0–73.0 vs 62.0
years, IQR 54.5–68.0; p <0.0001) and had a higher body
mass index than patients admitted in the previous pan-
demic period. They presented with lower SAPS II and
APACHE II scores, less need for circulatory support and
lower white blood cell counts at ICU admission. P/F ratio
was similar, but a 14% increase in ventilatory ratio was ob-
served over time (p = 0.03)
CONCLUSION: Near real-time registry data show that the
latest COVID-19 patients admitted to ICUs in Switzerland
at the onset of the third wave were on average 5 years
younger, had a higher body mass index, and presented
with lower physiological risk scores but a trend towards
more severe lung failure. These differences may primarily
be related to the ongoing nationwide vaccination cam-
paign, but the possibility that changes in virus-host inter-
actions may be a co-factor in the age shift and change in
disease characteristics is cause for concern, and should
be taken into account in the public health and vaccination
strategy during the ongoing pandemic. (ClinicalTrials.gov
Identifier: NCT04357275)
Introduction
The coronavirus disease (COVID)-19 pandemic, declared
on 17 March 2020 by the World Health Organization
(WHO), has burdened the global health systems without
recent precedent. A rapid international effort in uncovering
properties of the novel disease [1, 2] and optimal treatment
strategies [3–5] was followed by the launch of a large-scale
vaccination campaign [6, 7]. At the same time, virus mu-
tations [8, 9] have hinted at possible changes in (i) trans-
missibility and (ii) the virulence affecting disease progres-
sion up to critical illness and mortality [10], and carry
the potential for future vaccination failure. Over the last
12 months, a renewed increase in SARS-CoV-2 cases in
Switzerland and reported changes in virus properties, to-
gether with the inception of the vaccination campaign on
21 December 2020, underscore the need for continued
monitoring of the disease development over time. The pre-
sent report aims to provide a near real-time description of
the characteristics of COVID-19 patients admitted to in-
tensive care units (ICUs) at the onset of a third wave in
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Switzerland and compare these with the previous course of
the COVID-19 pandemic.
Methods
The present report is based on the prospective, near real-
time observational Risk Stratification in Covid-19 patients
in the ICU (RISC-19-ICU) registry, a tool launched on
17 March 2020 to track patient and disease characteristics
and the disease course of critically ill COVID-19 patients.
The registry is endorsed by the Swiss Society of Intensive
Care Medicine (https://www.sgi-ssmi.ch) and was exempt
from the need for additional ethics approval and patient in-
formed consent by the ethics committee of the University
of Zurich (KEK 2020-00322, ClinicalTrials.gov Identifier:
NCT04357275). The study complies with the Declaration
of Helsinki, the Guidelines on Good Clinical Practice
(GCP-Directive) issued by the European Medicines
Agency, as well as the Swiss law and Swiss regulatory
authority requirements, and has been designed in accor-
dance with the Strengthening the Reporting of Observa-
tional Studies in Epidemiology (STROBE) guidelines for
observational studies [11].
Study design and patient selection
The registry contained data from 3344 patients from 69
centres in 14 countries as of 31 May 2021. Given the
wide heterogeneity with regard to local viral epidemiology,
health care and ICU resources, here we focus only on pa-
tients admitted to ICUs in Switzerland. All records as of
31 May 2021 were exported from the registry and divided
into two groups. Patients admitted between 1 February and
31 May 2021 were considered to be admitted during a third
pandemic wave, based on the increasing number of posi-
tive test results for SARS-CoV-2 per 100,000 inhabitants,
number of hospitalised COVID-19 patients, and number
of COVID-19 patients treated in the ICU in Switzerland,
which were observed for the first time in February 2021
following the decline after the peak of the second wave of
SARS-CoV-2 infections (see fig. 1). Patients admitted be-
tween 1 March 2020 and 31 January 2021 were assigned to
a comparator group consisting of the patients admitted dur-
ing the first and second wave of SARS-CoV-2 infections
(see fig. 2).
Registry data collection and transformation
As described in detail elsewhere [1], a standardised core
dataset was prospectively collected during the ongoing
COVID-19 pandemic for all critically ill COVID-19 pa-
tients admitted to the collaborating centres, and up-to-date
cohort characteristics were regularly provided to the Swiss
ICUs throughout the pandemic. Inclusion criteria were (i) a
laboratory-confirmed SARS-CoV-2 infection diagnosed by
nucleic acid amplification according to the testing guide-
lines issued by the WHO [12], and (ii) requirement for
treatment in an ICU or intermediate care unit, defined as
a hospital ward specialised in the care of critically ill pa-
tients to provide organ support therapies including invasive
mechanical ventilation and/or noninvasive ventilation. Da-
ta were collected through an anonymised electronic case
report form managed by the REDCap electronic data cap-
ture tool hosted on a secure server by the Swiss Society
of Intensive Care Medicine [13]. Data were collected on
the day of ICU admission and on days one, two, three,
five and seven, including patient characteristics, treatment
modalities and organ support therapies, the use of mechan-
ical ventilation, vital parameters, arterial blood gas analy-
ses, and laboratory values such as inflammatory, coagula-
tion, renal, liver and cardiac parameters. The Swiss centres
enrolled in the RISC-19-ICU represented >60% of all cer-
tified secondary versus tertiary care centres in both the
North-Eastern and South-Western regions of Switzerland
(see supplementary table S1 in the appendix). Registry da-
ta transformation for analysis, including the calculation of
the disease severity scores Acute Physiology and Chronic
Health Evaluation (APACHE II), Simplified Acute Physi-
ology Score (SAPS II) and Sequential Organ Failure As-
sessment (SOFA) scores, was performed using an openly
available code library associated with the registry [14].
Statistical analysis
We report counts and percentages (%), mean and standard
deviation (SD) or median (interquartile range [IQR]), as
appropriate. The number of positive test results for SARS-
CoV-2 infections, number of hospitalised patients and
number of vaccine doses applied in Switzerland were pro-
vided by the Swiss Federal Office of Public Health (FOPH)
[15]. The overall absolute number of patients treated in
the ICU was provided by www.icumonitoring.ch / Koor-
dinierter Sanitätsdienst (KSD) and was stratified by age
using per-day age distributions derived from the
RISC-19-ICU registry. Patient characteristics, physiologi-
cal status and laboratory measurements at the time of ICU
admission were compared between the two groups (first
+ second vs third wave) using Gaussian (continuous out-
comes), logistic (binary outcomes) and Poisson (count out-
comes) mixed model analysis [16]. Time period was en-
tered into the model as a fixed effect and treatment centre
as random effect. P-values were calculated using a likeli-
hood ratio test of the full model with the effect in ques-
tion against a “null model” that lacks the effect in question
[17], p-values for individual fixed effects were obtained by
Satterthwaite approximation [18]. Changes in age distrib-
ution throughout both periods were adjusted for the num-
ber of comorbidities. Statistical analysis was performed us-
ing a fully scripted data management pathway using the R
environment for statistical computing version 3.6.3 [19].
Mixed effects modelling was performed using the R-li-
brary lme4, version 1.1.21 [16] and graphical output using
ggplot2, version 3.2.1 [20].
Results
Epidemiological environment
With regard to the third wave, an increase in the number
of positive test results for SARS-CoV-2 infections per
100,000 inhabitants in Switzerland was reported for the
first time in February 2021, after a continuous decrease
reported in December 2020 (fig. 1A). This increase was
reflected in the number of hospitalised patients (fig. 1B)
and absolute number of patients treated in the ICU (fig.
1C). The proportions of patients older and younger than
70 years remained stable from the initial phase of the pan-
demic, but shifted towards the younger patients at the onset
of the third wave. This effect was most pronounced in the
patients treated in the ICU. In Switzerland, a vaccination
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campaign using the BNT162b2 and mRNA-1273 SARS-
CoV-2 vaccines started on 21 December 2020. The cumu-
lative number of vaccines applied over time is shown in
figure 1D. According to official recommendations, the ma-
jority of vaccine doses were administered to persons above
the age of 75 years with pre-existing medical conditions as
of May 2021.
Differences in characteristics and age distribution in
critically ill COVID-19 patients
A total of 1829 patients admitted to Swiss ICUs were in-
cluded in the registry as of 31 May 2021. Of these, 1690
patients were admitted before 1 February and the remain-
ing 139 patients were admitted during the emerging third
pandemic wave (fig. 2). Patients assigned to the third wave
were a mean of 5.2 years (confidence interval [CI] 3.2–7.1)
younger (median 66.0 years, IQR 57.0-73.0 vs 62.0 years,
IQR 54.5–68.0; p <0.0001) as compared with the previous
pandemic period, corresponding to a marked left-shift in
Figure 1: The number of positive test results for SARS-CoV-2 per 100,000 inhabitants (A) indicates three pandemic wave periods, which are
reflected in the number of hospitalised patients (B) and absolute number of patients treated in the intensive care unit (ICU) (C). The propor-
tions of patients older and younger than 70 years remained stable throughout the first and second wave periods and from the onset of the third
wave period shifted towards the younger patients. This effect was most pronounced in the patients treated in the ICU. The total number of vac-
cine doses applied is given in (D). The data in (A, B, D) were provided by the Federal Office of Public Health (FOPH). The overall absolute
number of patients treated in the ICU as reported by www.icumonitoring.ch / Koordinierter Sanitätsdienst (KSD; C, green line) was stratified by
age using per-day age distributions derived from the RISC-19-ICU registry (C, blue and orange lines).
Original article Swiss Med Wkly. 2021;151:w20553
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 3 of 9
Figure 2: Patient enrolment within the RISC-19-ICU registry, patient selection and group assignment for the comparison of patients admitted
during the third wave of SARS-CoV-2 infections in Switzerland with the previous pandemic course.
the age distribution (fig 3A). Multivariable correction for
age and comorbidities confirmed the effect of time period
on age and revealed an effect on comorbidities (supple-
mentary table S2 in the appendix). In both time periods
taken together, approximately 80% of patients who had
died in the ICU were older than 60 years of age, and ap-
proximately 40% of the patients treated in the ICU were
younger than 60 years of age (fig. 3B). Third wave pa-
tients had a higher body mass index, and presented with
lower SAPS II and APACHE II scores, cardiovascular sys-
tem SOFA sub-score and need for norepinephrine support
at the time of ICU admission (table 1). P/F ratio was simi-
lar, but a 14% increase in ventilatory ratio was observed as
compared with patients from waves 1 and 2. White blood
cell count, creatinine and creatine kinase levels were found
to be lower, whereas the remaining characteristics, includ-
ing inflammatory markers, remained comparable (table 1).
Age-stratified patient characteristics at ICU admission are
shown in supplementary table S3.
Discussion
Here we present an up-to-date comparison of Swiss ICU
patients suffering from COVID-19 during the onset of the
third wave with the first and second waves. To do this
we analysed changes in the patient characteristics and out-
come based on near real-time registry data. The risk factors
for the development of critical illness in COVID-19, as
shown in a previous report from the RISC-19-ICU registry
[1], such as age, male sex, and preexisting conditions such
as obesity, cardiovascular disease, diabetes mellitus and
conditions associated with immune system compromise,
could be subject to changes in the population at risk, as
well a shifting properties of the disease itself. The shift to-
wards a younger age by more than 5 years is clearly ap-
parent even in an early stage of the onset of the third wave
of SARS-CoV-2 infections in Switzerland, and could be
highly relevant since a potentially altered course of dis-
ease could directly impact ICU resources. Although the
observed decrease in patients in the higher age groups is
most likely be related to the vaccination campaign that has
prioritised persons in the higher age groups, the observa-
tion of younger patients developing critical illness due to
COVID-19, with a higher overall number of comorbidities
and, specifically, prevalence of ischaemic heart disease,
alongside the higher body mass index found in the present
study, would not be expected with the current, risk-based
vaccination strategy and could be related to an increasing
prevalence of virus variants. Further, the younger age of
patients admitted during the third wave does not solely ex-
plain per se the decrease in physiological risk scores such
as SAPS II and APACHE II. Whereas the need for circu-
latory support was indeed reduced during the third wave,
which may suggest better compensation mechanisms, as
was found in previous research [21], we have observed an
Figure 3: The age distribution of patients admitted to the in-
tesnsive care unit (ICU) (A) shifted towards younger patients at the
onset of the third wave of SARS-CoV-2 infections in Switzerland in
comparison with the previous pandemic course. Overall, the ICU
mortality (B) is accounted with approximately 80% to patients older
that 60 years of age, whereas approximately 40% of the patients
treated in the ICU were younger than 60 years of age.
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Table 1: Characteristics of critically ill COVID-19 patients at ICU admission at the onset of the third wave of SARS-CoV-2 infections in Switzerland in comparison with the previ-
ous pandemic course.
01.03.2020 – 31.01.2021; 2019
SARS-CoV-2 pandemic waves
1 and 2
01.02.2021 – 15.04.2021; onset
of 2019 SARS-CoV-2 pandem-
ic wave 3
Mean difference ± SE (CI) for
continuous variables, rate ra-
tio (CI) for counts, odds ratio
(CI) for binary categorical




n = 1690 n = 139
Characteristics
Age (years), median (IQR) 66 (57–73) 62 (54–68) −5.2 ± 1.2 (−7.1 to −3.2) <0.0001
Sex (male), n (%) 1227 (73.4) 98 (70.5) 0.9 (0.6 to 1.3) 0.46
Body mass index (kg·m-2), mean (SD) 29.3 (6.0) 30.5 (6.2) 1.2 ± 0.5 (0.3 to 2.1) 0.03
Time from symptom onset to hospitalisation (days),
mean (SD)
8.5 (8.5) 8.6 (6.6) 0.1 ± 0.8 (−1.2 to 1.4) 0.91
Time from hospitalisation to ICU admission (days),
mean (SD)
3.0 (8.2) 2.6 (4.6) -0.3 ± 0.7 (-1.5 - 0.9) 0.67
Preexisting conditions
Number of preexisting conditions, mean (SD) 0.9 (1.1) 0.7 (1.0) 0.8 (0.7 to 1.0) 0.06
Ischaemic heart disease, n (%) 790 (46.7) 50 (36.0) 0.5 (0.3 to 0.7) <0.001
Chronic heart failure, n (%) 228 (13.5) 11 (7.9) 0.5 (0.3 to 1.0) 0.06
Atherosclerotic arteriopathy, n (%) 270 (16.0) 19 (13.7) 0.7 (0.4 to 1.2) 0.23
Arterial hypertension, n (%) 466 (27.6) 32 (23.0) 0.8 (0.5 - 1.2) 0.23
Diabetes mellitus, n (%) 223 (13.2) 15 (10.8) 0.9 (0.5 to 1.6) 0.68
Insulin-dependent diabetes mellitus, n (%) 263 (15.6) 16 (11.5) 0.7 (0.4 to 1.3) 0.29
Physiological status at ICU admission
APACHE II score, mean (SD) 17.2 (7.8) 16.1 (7.1) −1.4 ± 0.7 (−2.6 to −0.3) 0.04
SAPS II score, mean (SD) 47.8 (19.6) 43.1 (18.6) −4.5 ± 1.7 (−7.4 to −1.7) <0.01
SOFA score, mean (SD) 10.9 (5.3) 11.2 (4.1) −0.8 ± 0.5 (−1.5 to 0) 0.10
– Respiratory system sub-score, mean (SD) 2.4 (1.2) 2.5 (1.0) −0.1 ± 0.1 (−0.3 to 0.1) 0.38
– Coagulatory system sub-score, mean (SD) 0.2 (0.6) 0.2 (0.5) −0.1 ± 0.05 (−0.1 to 0.0) 0.38
– Liver sub-score, mean (SD) 2.2 (1.6) 2.6 (1.3) −0.1 ± 0.14 (−0.3 to 0.2) 0.59
– Cardiovascular system sub-score, mean (SD) 1.5 (1.6) 1.2 (1.5) −0.5 ± 0.15 (−0.7 to −0.2) <0.01
– Central nervous system sub-score, mean (SD) 1.8 (1.9) 1.2 (1.9) -0.3 ± 0.17 (-0.6 - -0.02) 0.07
– Renal sub-score, mean (SD) 3.4 (1.4) 3.9 (0.6) 0.0 ± 0.11 (−0.2 to 0.2) 0.83
Mean arterial pressure (mm Hg), mean (SD) 83.3 (17.5) 89.6 (18.0) 5.1 ± 1.6 (2.4 to 7.8) <0.01
Norepinephrine dose (µg·kg-1), mean (SD) 5.0 (9.0) 1.9 (4.4) −2.0 ± 0.9 (−3.5 to −0.4) 0.03
P/F ratio (mmHg), mean (SD) 143 (103) 129 (200) −12.2 ± 11.9 (−31.8 to 7.5) 0.31
Ventilatory ratio, mean (SD) 1.8 (0.8) 2.1 (1.1) 0.2 ± 0.1 (0.1 to 0.3) 0.03
Laboratory measurements at ICU admission
White blood cell count (G·l-1), mean (SD) 9.9 (6.1) 9.0 (4.6) −1.4 ± 0.6 (−2.4 to −0.3) 0.03
Neutrophil granulocyte count (G·l-1), mean (SD) 8.2 (4.8) 7.6 (4.1) −0.9 ± 0.6 (−1.987 to 0.0) 0.11
Lymphocyte count (G·l-1), mean (SD) 1.3 (2.6) 1.5 (2.0) −0.6 ± 0.3 (−1.1 to −0.1) 0.06
Neutrophil/lymphocyte ratio, mean (SD) 13.0 (13.6) 11.1 (10.1) −0.9 ± 1.6 (−3.5 to 1.8) 0.59
Interleukin-6 (ng·l-1), median (IQR) 103 (40–246) 92 (61–144) −321.6 ± 886.4 (−1789.6 to
1156.7)
0.72
C-reactive protein (mg·l-1), median (IQR) 141 (78–214) 141 (87–210) −1.9 ± 9.9 (−18.2 to 14.5) 0.85
Procalcitonin (µg·l-1), median (IQR) 0.3 (0.2–0.9) 0.2 (0.1–0.4) −1.6 ± 1 (−3.3 to 0.0) 0.10
D-dimers (µg·l-1), median (IQR) 1545 (890–3420) 1240 (770–3000) 34.1 ± 1948.0 (−3204.3 to
3255.1)
0.99
Lactate dehydrogenase (U·l-1), median (IQR) 517 (382–693) 522 (411–663) 27.6 ± 44.4 (−45.5 to 100.6) 0.53
Ferritin (µg·l-1), median (IQR) 1174 (651–1973) 1231 (775–1902) −349.6 ± 253.7 (−767.3 to 70.0) 0.17
Bilirubin (µmol·l-1), median (IQR) 9.0 (6.3–13.0) 9.0 (5.8–12.0) −6.2 ± 10.5 (−23.5 to 11.1) 0.55
Creatinine (µmol·l-1), median (IQR) 84 (66–115) 67 (53–88) −27.9 ± 11.7 (−47.1 to −8.8) 0.02
Creatine kinase (U·l-1), median (IQR) 119 (60–269) 118 (56–276) 832.3 ± 284.8 (358.3 to 1313.6) < 0.01
Myoglobin (µg·l-1), median (IQR) 79 (41–221) 52 (36–106) 55.7 ± 510.7 (−787.1 to 899.2) 0.91
Troponin (ng·l-1), median (IQR) 21.1 (11.0–55.0) 20.9 (9.3–65.8) −347.5 ± 431.7 (−1060.1 to
364.6)
0.42
Albumin (g·l-1), median (IQR) 29 [26–33) 30 (27–33) −0.4 ± 0.8 (−1.7 to 0.9) 0.63
SE = standard error; CI = 95% confidence interval; SD = standard deviation; IQR = interquartile range Values are given as counts and percentages (%), mean (SD) or median
(IQR), as appropriate. The effect of time period is represented by estimates, confidence intervals and p-values derived from mixed model analysis with time period entered as
fixed effect and treatment centre as random effect. Estimates are given as the mean difference ± SE (CI) for continuous variables, rate ratio (CI) for counts, and odds ratio (CI) for
binary categorical variables.
unexpected trend towards more severe lung failure. A re-
cent study reported an increase in mortality in patients in-
fected with the B1.1.7 variant of the SARS-CoV-2 virus
[10], demonstrating a relationship between changes in viral
epidemiology and disease course. Further studies are need-
ed to confirm whether our observations reflect the vaccina-
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tion status or whether this truly reflects a different patho-
physiological behaviour of the virus.
Since the inception of the pandemic, the dataset shows that
the majority of the patients dying in the ICU were older
than 60 years. However, almost half of the patients treated
in the ICU were younger than 60 years of age. Long-term
outcome studies in patients with non-COVID acute respi-
ratory distress syndrome (ARDS) have demonstrated that
only approximately 50% of working-age ICU survivors
have been able to take up employment after 1 year [22]. As
younger patients make up a relevant proportion of critical-
ly ill COVID-19 patients, it might make sense to prioritise
the vaccination of patients between 40 and 60 years of age
regardless of their health risk profile, but based on occupa-
tional risk.
The main limitation of near real-time data during an
emerging pandemic is the unavailability of outcome data
due to selection bias of these parameters in patients with
shorter ICU stays. By limiting to the description of the pa-
tient characteristics in the comparison of the two time pe-
riods, this bias was avoided in the present report, while
using the near real-time registry to provide timely surveil-
lance of changes regarding patients who develop critical
illness due to this novel disease. Further, the observational
nature of the study determined the unbalanced sample sizes
of both groups with heterogeneity across treatment centres.
The mixed model approach accounts for such complexities
while allowing for partial pooling of information [23].
In conclusion, near real-time registry data show that the
latest COVID-19 patients admitted to ICUs in Switzerland
at the onset of the third wave were on average 5 years
younger, had a higher body mass index, and presented with
lower physiological risk scores but a trend towards more
severe lung failure. These differences may primarily be re-
lated to the ongoing nationwide vaccination campaign, but
the possibility that changes in virus-host interactions may
be a co-factor in the age shift and change in disease charac-
teristics is cause for concern that should be taken into ac-
count in the public health and vaccination strategy during
the ongoing pandemic.
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Appendix: Supplementary tables
Table S1: Intensive care units enrolled in the RISC-19-ICU registry in Switzerland with the centres’ role and region.
Intensive care units enrolled in the RISC-19-ICU registry, n (%) Type Region
4 (80%) Tertiary care centre Switzerland, South-West
5 (100%) Tertiary care centre Switzerland, North-East
14 (70%) Secondary care centre Switzerland, South-West
34 (64%) Secondary care centre Switzerland, North-East
Table S2: Uni- and multivariable linear mixed model analysis adjusting for the number of comorbidities confirmed the effect of time period on patient age at the onset of the third
wave of SARS-CoV-2 infections in Switzerland in comparison to the previous pandemic course. Multivariable analyses further revealed an effect of time period on the number of
comorbidities when corrected for age. In these models, treatment centre was added as random effect and the p values of individual fixed effects were estimated using the Sat-
terthwaite approximation.
Univariable analysis, fixed effects Mean difference estimate ± SE
(95% CI)
t value p-value
Time period −5.17 ± 1.17
(−7.47 to −2.85)
−4.40 <0.0001
Univariable analysis, random effects Variance ± SD
Treatment centre 3.46 ± 1.86
Multivariable analysis, fixed effects Mean difference estimate ± SE
(95% CI)
t value p value
Number of comorbidities 3.37 ± 0.29
(2.76 to 3.94)
11.52 <0.0001
Time period −4.59 ± 1.14
(−6.81 to −2.33)
−4.02 < 0.0001
Multivariable analysis, random effects Variance ± SD
Treatment centre 4.48 ± 2.12
SD = standard deviation; SE = standard error; CI = 95% confidence interval.
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Table S3: Characteristics of critically ill COVID-19 patients at ICU admission at the onset of the third wave of SARS-CoV-2 infections in Switzerland in comparison with the previ-
ous pandemic course, stratified by age groups.
01.03.2020 – 31.01.2021; 2019 SARS-CoV-2 pan-
demic waves 1 and 2
01.02.2021 – 15.04.2021; onset of 2019 SARS-CoV-2
pandemic wave 3
70 yrs or older <70 yrs 70 yrs or older <70 yrs
n = 671 n = 1158 n = 25 n = 114
Characteristics
Age (years), median (IQR) 75 (72–79) 60 (53–65) 72 (70–75) 59 (52–65)
Sex (male), n (%) 437 (71.9) 778 (74.5) 21 (84.0) 77 (67.5)
Body mass index (kg·m-2), mean (SD) 28.2 (5.1) 29.9 (6.4) 29.5 (6.0) 30.7 (6.3)
Time from symptom onset to hospitalisation (days), mean
(SD)
8.6 (11.3) 8.4 (6.3) 8.7 (9.1) 8.5 (5.9)
Time from hospitalisation to ICU admission (days), mean
(SD)
3.6 (11.1) 2.6 (5.8) 4.0 (6.4) 2.3 (4.1)
Preexisting conditions
Number of preexisting conditions, mean (SD) 1.2 (1.2) 0.8 (1.0) 1.2 (1.3) 0.6 (0.9)
Ischaemic heart disease, n (%) 354 (58.1) 435 (41.4) 10 (40.0) 40 (35.1)
Chronic heart failure, n (%) 133 (21.8) 95 (9.0) 6 (24.0) 5 (4.4)
Atherosclerotic arteriopathy, n (%) 149 (24.5) 121 (11.5) 7 (28.0) 12 (10.5)
Arterial hypertension, n (%) 213 (35.0) 253 (24.1) 9 (36.0) 23 (20.2)
Diabetes mellitus, n (%) 91 (14.9) 132 (12.6) 6 (24.0) 9 (7.9)
Insulin-dependent diabetes mellitus, n (%) 104 (17.1) 159 (15.1) 6 (24.0) 10 (8.8)
Physiological status at ICU admission
APACHE II score, mean (SD) 19.1 (7.1) 16.5 (7.7) 17.4 (6.3) 15.8 (7.3)
SAPS II score, mean (SD) 53.1 (17.7) 45.7 (19.5) 46.0 (16.4) 42.5 (19.1)
SOFA score, mean (SD) 11.3 (5.1) 10.9 (5.2) 11.3 (3.8) 11.2 (4.2)
– Respiratory system sub-score, mean (SD) 2.4 (1.1) 2.4 (1.2) 2.3 (1.0) 2.6 (1.0)
– Coagulatory system sub-score, mean (SD) 0.3 (0.6) 0.2 (0.6) 0.4 (0.7) 0.1 (0.4)
– Liver sub-score, mean (SD) 2.2 (1.6) 2.2 (1.6) 2.8 (1.4) 2.6 (1.3)
– Cardiovascular system sub-score, mean (SD) 1.8 (1.7) 1.4 (1.6) 1.3 (1.4) 1.2 (1.5)
– Central nervous system sub-score, mean (SD) 1.7 (1.9) 1.8 (2.0) 0.8 (1.6) 1.3 (1.9)
– Renal sub-score, mean (SD) 3.4 (1.3) 3.4 (1.4) 4.0 (0.0) 3.9 (0.7)
Mean arterial pressure (mm Hg), mean (SD) 82.1 (18.5) 84.0 (16.8) 84.2 (21.9) 90.8 (16.9)
Norepinephrine dose (µg·kg-1), mean (SD) 5.9 (8.6) 4.5 (9.2) 1.5 (2.7) 2.0 (4.7)
P/F ratio (mmHg), mean (SD) 148 (120) 139 (92) 108 (59) 133 (219)
Ventilatory ratio, mean (SD) 1.8 (0.7) 1.9 (0.8) 1.8 (0.7) 2.2 (1.2)
Laboratory measurements at ICU admission
White blood cell count (G·l-1), mean (SD) 10.0 (5.5) 9.9 (6.5) 10.8 (5.5) 8.5 (4.3)
Neutrophil granulocyte count (G·l-1), mean (SD) 8.3 (4.5) 8.1 (4.9) 9.3 (4.6) 7.1 (3.9)
Lymphocyte count (G·l-1), mean (SD) 1.4 (3.1) 1.3 (2.4) 1.0 (1.6) 1.6 (2.1)
Neutrophil/lymphocyte ratio, mean (SD) 14.4 (13.9) 12.2 (13.4) 17.0 (12.5) 9.3 (8.6)
Interleukin-6 (ng·l-1), median (IQR) 129 (51–306) 98 (36–228) 114 (60–133) 89 (64–148)
C-reactive protein (mg·l-1), median (IQR) 137 (74–201) 144 (82–220) 133 (93–246) 141 (87–204)
Procalcitonin (µg·l-1), median (IQR) 0.3 (0.2–0.9) 0.3 (0.2–0.8) 0.3 (0.2–1.3) 0.2 (0.1–0.4)
D-dimers (µg·l-1), median (IQR) 1504 (880–3413) 1349 (830–2800) 1165 (763–2455) 1900 (1120–4315)
Lactate dehydrogenase (U·l-1), median (IQR) 501 (362–676) 527 (395–697) 526 (465–843) 522 (407–644)
Ferritin (µg·l-1), median (IQR) 1106 (601–1823) 1239 (701–2034) 1508 (840–2216) 1132 (769–1701)
Bilirubin (µmol·l-1), median (IQR) 9.0 (6.4–13.0) 9.0 (6.2–13.1) 10.1 (7.0–14.0) 8.0 (5.2–12.0)
Creatinine (µmol·l-1), median (IQR) 91 (71–139) 79 (63–104) 84 (67–114) 63 (50–84)
Creatine kinase (U·l-1), median (IQR) 107 (54–257) 124 (64–303) 101 (56–232) 126 (58–283)
Myoglobin (µg·l-1), median (IQR) 85 (45–179) 74 (40–241) 172 (51–227) 52 (27–92)
Troponin (ng·l-1), median (IQR) 35.0 (19.0–95.2) 15.6 (9.0–42.7) 35.8 (26.9–69.8) 15.0 (8.4–45.0)
Albumin (g·l-1), median (IQR) 29 (25–32) 30 (26–33) 30 (26–33) 30 (27–33)
SD = standard deviation; IQR = interquartile range
Values are given as counts and percentages (%), mean (SD) or median (IQR), as appropriate.
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